Current report on the interferon program at Roswell Park Memorial Institute

Area of Science:

• Immunology
• Virology
• Oncology
• Pharmacology

Background:

• Overview of the interferon research program at Roswell Park Memorial Institute (RPMI).
• Focus on three key areas: basic research, large-scale manufacturing, and clinical applications of interferons.

Purpose of the Study:

• To present the interferon program at RPMI, detailing research and drug development.
• To evaluate the safety, antiviral, antitumor, and immunomodulatory effects of human fibroblast interferon (HFIF).

Main Methods:

• Basic research on interferon purification and characterization.
• Large-scale manufacturing and preclinical testing of HFIF.
• Phase I clinical trials assessing HFIF safety and efficacy via various administration routes (SC, IM, IV, intrathecal).

Main Results:

• HFIF demonstrated a 71% local response rate in metastatic nodules via intralesional injection.
• Phase I trials in 13 patients showed HFIF is safe across multiple administration routes up to 25 million units/day.
• Significant HFIF levels were detected in serum and cerebrospinal fluid.
• Favorable immune and clinical responses were observed during HFIF administration.

Conclusions:

• HFIF produced at RPMI exhibits significant antitumor activity and is safe for patient administration.
• The observed safety and efficacy profile supports further clinical trials (Phase II and III).